| Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study AJH Kind, S Jencks, J Brock, M Yu, C Bartels, W Ehlenbach, C Greenberg, ... Annals of internal medicine 161 (11), 765-774, 2014 | 1052 | 2014 |
| Nf1-dependent tumors require a microenvironment containing Nf1+/−-and c-kit-dependent bone marrow FC Yang, DA Ingram, S Chen, Y Zhu, J Yuan, X Li, X Yang, S Knowles, ... Cell 135 (3), 437-448, 2008 | 400 | 2008 |
| CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis L Wang, Z Zhao, MB Meyer, S Saha, M Yu, A Guo, KB Wisinski, W Huang, ... Cancer cell 25 (1), 21-36, 2014 | 317 | 2014 |
| Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis S Seng, Z Liu, SK Chiu, T Proverbs-Singh, G Sonpavde, TK Choueiri, ... Journal of clinical oncology 30 (35), 4416-4426, 2012 | 285 | 2012 |
| Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy SG Zhao, SL Chang, N Erho, M Yu, J Lehrer, M Alshalalfa, C Speers, ... JAMA oncology 3 (12), 1663-1672, 2017 | 283 | 2017 |
| Prevalence of human papillomavirus in oropharyngeal cancer: a systematic review AP Stein, S Saha, JL Kraninger, AD Swick, M Yu, PF Lambert, RJ Kimple The Cancer Journal 21 (3), 138-146, 2015 | 272 | 2015 |
| Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial KA Robertson, G Nalepa, FC Yang, DC Bowers, CY Ho, GD Hutchins, ... The lancet oncology 13 (12), 1218-1224, 2012 | 257 | 2012 |
| Advanced cognitive training for breast cancer survivors: a randomized controlled trial D Von Ah, JS Carpenter, A Saykin, P Monahan, J Wu, M Yu, G Rebok, ... Breast cancer research and treatment 135, 799-809, 2012 | 239 | 2012 |
| Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis SG Zhao, SL Chang, DE Spratt, N Erho, M Yu, HAD Ashab, M Alshalalfa, ... The lancet oncology 17 (11), 1612-1620, 2016 | 223 | 2016 |
| Joint longitudinal-survival-cure models and their application to prostate cancer M Yu, NJ Law, JMG Taylor, HM Sandler Statistica Sinica, 835-862, 2004 | 215 | 2004 |
| Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma JM Wu, Y Xu, NJ Skill, H Sheng, Z Zhao, M Yu, R Saxena, MA Maluccio Molecular cancer 9, 1-14, 2010 | 171 | 2010 |
| Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor RJ Chan, MB Leedy, V Munugalavadla, CS Voorhorst, Y Li, M Yu, ... Blood 105 (9), 3737-3742, 2005 | 168 | 2005 |
| Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells CE Barcus, KA O’Leary, JL Brockman, DE Rugowski, Y Liu, N Garcia, ... Breast Cancer Research 19, 1-13, 2017 | 149 | 2017 |
| A general statistical framework for subgroup identification and comparative treatment scoring S Chen, L Tian, T Cai, M Yu Biometrics 73 (4), 1199-1209, 2017 | 148 | 2017 |
| Association of neighborhood-level disadvantage with Alzheimer disease neuropathology WR Powell, WR Buckingham, JL Larson, L Vilen, M Yu, MS Salamat, ... JAMA network open 3 (6), e207559-e207559, 2020 | 137 | 2020 |
| Individual prediction in prostate cancer studies using a joint longitudinal survival–cure model M Yu, JMG Taylor, HM Sandler Journal of the American Statistical Association 103 (481), 178-187, 2008 | 136 | 2008 |
| Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial AM Moore, LH Einhorn, D Estes, R Govindan, J Axelson, J Vinson, ... Lung Cancer 52 (1), 93-97, 2006 | 136 | 2006 |
| Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer MD Galsky, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, ... Journal of Clinical Oncology 38 (16), 1797-1806, 2020 | 135 | 2020 |
| Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes MD Galsky, H Wang, NM Hahn, P Twardowski, SK Pal, C Albany, ... European urology 73 (5), 751-759, 2018 | 127 | 2018 |
| Neighborhood socioeconomic disadvantage and 30 day rehospitalizations: an analysis of Medicare data AJH Kind, S Jencks, J Brock, M Yu, C Bartels, W Ehlenbach, C Greenberg, ... Annals of internal medicine 161 (11), 765, 2014 | 115 | 2014 |